Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458016 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00458016: Completed Phase 2 study, sponsored by Ligand Pharmaceuticals.
NCT00458016 is a Phase 2 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 105 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (21% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00458016, a Phase 2 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to collect important information regarding the safety, tolerability, and efficacy of MB07803 when administered for 28 days in patients with type 2 diabetes mellitus
Interventions
- DRUG Placebo
- DRUG MB07803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
What the finished NCT00458016 record still lists
NCT00458016 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (21% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00458016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00458016 about?
NCT00458016 is a clinical study titled "Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus". The purpose of this study is to collect important information regarding the safety, tolerability, and efficacy of MB07803 when administered for 28 days in patients with type 2 diabetes mellitus
What is the current status of trial NCT00458016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2007-03. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00458016?
The interventions under investigation include: Placebo (DRUG), MB07803 (DRUG).
Who is sponsoring clinical trial NCT00458016?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00458016's enrollment target sits among peer trials
105 650th of 2000 higher than 1,341 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia